Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.33 |
| ▸ | BRD4 | O60885 | 4/20 | 0.33 |
| ▸ | TAF1 | P21675 | 4/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 4/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8436781 | 0.89 | CYP11B2 (0.33) | BACE1CYP11B2CYP11B1BRD4TAF1 | |
| SCHEMBL4549211 | 0.88 | BACE1 (0.49) | BACE1BACE2 | |
| SCHEMBL4556664 | 0.84 | BACE1 (0.36) | BACE1CYP11B2CYP11B1CYP2A6BACE2 | |
| SCHEMBL4556855 | 0.82 | CYP11B2 (0.34) | BACE1CYP11B2CYP11B1BRD4TAF1 | |
| SCHEMBL10186918 | 0.81 | BACE1 (0.37) | BACE1CYP11B2CYP11B1CYP2A6BACE2 | |
| SCHEMBL13081669 | 0.81 | CYP11B2 (0.36) | BACE1CYP11B2CYP11B1CYP2A6 | |
| SCHEMBL4559930 | 0.81 | CYP2A6 (0.33) | BACE1CYP11B2CYP11B1BRD4TAF1 | |
| SCHEMBL4556908 | 0.81 | BACE1 (0.46) | BACE1CYP11B2CYP11B1BRD4TAF1 | |
| SCHEMBL4557086 | 0.80 | CCR1 (0.31) | — | |
| SCHEMBL8437087 | 0.79 | BRD4 (0.32) | BACE1BRD4TAF1ATAD2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232064-A1 | ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2012-09-13 | — | — | US | disclosed |
| US-8168641-B2 | Aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-01 | — | — | US | disclosed |
| US-20070287692-A1 | ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232064-A1 | ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, BACE1 | BACE1 3/4885CYP11B2 2150/4885CYP11B1 1364/4885 |
| US-20070287692-A1 | ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, BACE1 | BACE1 3/4885CYP11B2 2150/4885CYP11B1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.